In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia, discussed results of a post hoc analysis of the CANDELA study. Dr Fein described the primary and secondary endpoints and the potential clinical impact of the findings.
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions.…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
